Contact UsBiological Products
> Biopharmaceutical Industry Insight & News > Biological Products
| Product | Truxima? | Company | Celltrion, Inc. |
|---|---|---|---|
| Classification | Biosimilar | Active Ingredient | Rituximab |
| Reference Product | Rituximab | Approval Date | 2016 |
| Indication | Non-Hodgkin’s lymphoma (NHL), Chronic lymphocytic leukaemia (CLL), Rheumatoid arthritis, Granulomatosis with polyangiitis and microscopic polyangiitis | ||
| Description |
A monoclonal antibody biosimilar approved by MFDS in 2016.
Truxima is an antibody against CD20 intended for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis |
||
Korea Biomedicine Industry Association(KoBIA)
Address: 12, Teheran-ro 78-gil, Gangnam-gu, Seoul, Republic of Korea Tel: +82-2-725-8438 E-mail: info@kobia.kr
Address: 12, Teheran-ro 78-gil, Gangnam-gu, Seoul, Republic of Korea Tel: +82-2-725-8438 E-mail: info@kobia.kr
COPYRIGHT BY KoBIA. ALL RIGHTS RESERVED.